Login / Signup

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.

Kim A PappSaskia de VenteJiewei ZengMary FlackByron PadillaStephen K Tyring
Published in: Dermatology and therapy (2021)
ClinicalTrials.gov identifier; NCT02203851.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • study protocol
  • clinical trial
  • coronary artery disease
  • phase ii study
  • high intensity
  • drug induced
  • randomized controlled trial
  • double blind
  • radiation therapy